The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Trufanov S.V.

Research Institute of Eye Diseases

Subbot A.M.

M.M. Krasnov Research Institute of Eye Diseases

Shakhbazyan N.P.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Modern biotechnological treatment methods of persistent corneal epithelial defects

Authors:

Trufanov S.V., Subbot A.M., Shakhbazyan N.P.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(5): 277‑282

DOI: 10.17116/oftalma2020136052277

Views: 1561

Downloaded: 86

Download PDF (RU)
Contact the author
Table of contents

MODERN BIOTECHNOLOGICAL TREATMENT METHODS OF PERSISTENT CORNEAL EPITHELIAL DEFECTS
MODERN BIOTECHNOLOGICAL TREATMENT METHODS OF PERSISTENT CORNEAL EPITHELIAL DEFECTS

To cite this article:

Trufanov SV, Subbot AM, Shakhbazyan NP. Modern biotechnological treatment methods of persistent corneal epithelial defects. Russian Annals of Ophthalmology. 2020;136(5):277‑282. (In Russ.)
https://doi.org/10.17116/oftalma2020136052277

Подписка 2025-2 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Significance of cell therapy in treatment of patients with thin endo­metrium and Ashe­rman’s syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):42-48
Standardized and scalable method for stro­mal-vascular fraction harvesting from adipose tissue. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(4):76-81

The article reviews modern methods of treatment of persistent corneal epithelial defects and considers the factors involved in the development of this pathology, including the limbal stem cell deficiency, which is likely to play the main role. The most promising treatment methods are described, particularly the use of blood derivatives and cell therapy.

Keywords:

persistent corneal epithelial defect
limbal stem cell deficiency
autologous serum
platelet-rich plasma
cell therapy

Authors:

Trufanov S.V.

Research Institute of Eye Diseases

Subbot A.M.

M.M. Krasnov Research Institute of Eye Diseases

Shakhbazyan N.P.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Received:

13.06.2019

Accepted:

20.08.2019

List of references:

  1. Shimazaki J, Saito H, Yang HY, Toda I, Fujishima H, Tsubota K. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea.1995;14(6):623-627. 
  2. McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Transactions of the American Ophthalmological Society. 1993;91:367-390. 
  3. Erdem E, Yagmur M, Harbiyeli I, Taylan-Sekeroglu H, Ersoz R. Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects. International journal of ophthalmology. 2014;7(5):807.  https://doi.org/10.3980/j.issn.2222-3959.2014.05.12
  4. Fu Y, Liu J, Tseng SC. Ocular surface deficits contributing to persistent epithelial defect after penetrating keratoplasty. Cornea. 2012;31(7):723-729.  https://doi.org/10.1097/ICO.0b013e31821142ee
  5. Makarov PV, Kugusheva AE, Slepova OS, Chencova EV, Hazamova A I. On persistent erosions of the corneal transplant. (Part 2). Rossijskij oftal’mologicheskij zhurnal. 2015;8(2):41-46. (In Russ.).
  6. Gonzalez G, Sasamoto Y, Ksander BR, Frank MH, Frank NY. Limbal stem cells: identity, developmental origin, and therapeutic potential. Wiley Interdisciplinary Reviews: Developmental Biology. 2018;7(2):318.  https://doi.org/10.1002/wdev.303
  7. Kinoshita S, Adachi W, Sotozono C, Nishida K, Yokoi N, Quantock AJ, Okubo K. Characteristics of the human ocular surface epithelium. Progress in retinal and eye research. 2001;20(5):639-673.  https://doi.org/10.1016/S1350-9462 (01)00007-6
  8. Yoon JJ, Ismail S, Sherwin T. Limbal stem cells: Central concepts of corneal epithelial homeostasis. World journal of stem cells. 2014;6(4):391.  https://doi.org/10.4252/wjsc.v6.i4.391
  9. Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi Journal of Ophthalmology. 2014;28(3):168-172.  https://doi.org/10.1016/j.sjopt.2014.06.011
  10. Ziaei M, Greene C, Green C R. Wound healing in the eye: Therapeutic prospects. Advanced drug delivery reviews. 2018;126:162-176.  https://doi.org/10.1016/j.addr.2018.01.006
  11. Wagoner MD, Ba-Abbad R, Al-Mohaimeed M, Al-Swailem S, Zimmerman MB. Postoperative complications after primary adult optical penetrating keratoplasty: prevalence and impact on graft survival. Cornea. 2009;28(4): 385-394.  https://doi.org/10.1097/ICO.0b013e31818d3aef
  12. Wilson SE. Graft failure after penetrating keratoplasty. Survey of ophthalmology. 1990;34(5):325-356.  https://doi.org/10.1016/0039-6257(90)90110-H
  13. Constantinou M, Jhanji V, Tao LW, Vajpayee RB. Clinical review of corneal ulcers resulting in evisceration and enucleation in elderly population. Graefe’s archive for clinical and experimental ophthalmology. 2009;247(10):1389-1393. https://doi.org/10.1007/s00417-009-1111-9
  14. Rezende RA, Uchoa UB, Raber IM, Rapuano CJ, Laibson PR, Cohen EJ. New onset of herpes simplex virus epithelial keratitis after penetrating keratoplasty. American journal of ophthalmology. 2004;137(3):415-419.  https://doi.org/10.1016/j.ajo.2003.09.057
  15. Ricci F, Missiroli F, Ciotti M, Perno CF, Cerulli L. Persistent epithelial defect after penetrating keratoplasty caused by adenoviral infectious keratitis. The new microbiologica. 2004;33(2):171. 
  16. Mannis MJ, Plotnik RD, Schwab IR, Newton RD. Herpes simplex dendritic keratitis after keratoplasty. American journal of ophthalmology. 1991;111(4): 480-484.  https://doi.org/10.1016/S0002-9394(14)72384-0
  17. Gasset AR, Kaufman HE. Hydrophilic lens therapy of severe keratoconjunctivitis sicca and conjunctival scarring. American journal of ophthalmology. 1971;71(6):1185-1189. https://doi.org/10.1016/0002-9394(71)90960-3
  18. He X, Donaldson KE, Perez VL, Sotomayor P. Case series: overnight wear of scleral Lens for persistent epithelial defects. Optom Vis Sci. 2018;95(1):70-75.  https://doi.org/10.1097/OPX.0000000000001162
  19. Chiu GB, Theophanous C, Irvine JA. PROSE treatment in atypical ocular graft-versus-host disease. Optometry and Vision Science. 2016;93(11): 1444-1448. https://doi.org/10.1097/OPX.0000000000001003
  20. Khan M, Manuel K, Vegas B, Yadav S, Hemmati R, Al-Mohtaseb Z. Case series: Extended wear of rigid gas permeable scleral contact lenses for the treatment of persistent corneal epithelial defects. Contact Lens and Anterior Eye. 2019;42(1):117-122.  https://doi.org/10.1016/j.clae.2018.09.004
  21. Lim P, Ridges R, Jacobs DS, Rosenthal P. Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface. Am J Ophthalmol. 2013;156 (6). https://doi.org/1095-1101.10.1016/j.ajo.2013.06.006
  22. Jirsova K, Jones G. Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting — a review. Cell and tissue banking. 2017;18(2):193-204.  https://doi.org/10.1007/s10561-017-9618-5
  23. Wu MF, Stachon T, Langenbucher A, Seitz B, Szentmáry N. Effect of amniotic membrane suspension (AMS) and amniotic membrane homogenate (AMH) on human corneal epithelial cell viability, migration and proliferation in vitro. Current eye research. 2017:42(3):351-357.  https://doi.org/10.1080/02713683.2016.1192193
  24. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Progress in retinal and eye research. 2000;19(1):113-129.  https://doi.org/10.1016/S1350-9462(99)00007-5
  25. Holland S, Morck D, Schultz C. Treatment of corneal defects with delayed re‐epithelization with a medical device/drug delivery system for epidermal growth factor. Clinical & experimental ophthalmology. 2012;40(7):662-668.  https://doi.org/10.1111/j.1442-9071.2012.02795.x
  26. Schultz CL, Morck DW. Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Clinical and Experimental Optometry. 2010;93(2):61-65.  https://doi.org/10.1111/j.1444-0938.2010.00459.x
  27. Dellaert MJ, Casey TA, Wiffen S, Gordon J, Johnson P, Geerards AJM, Beekhuis W. H. Influence of topical human epidermal growth factor on postkeratoplasty re-epithelialisation. British journal of ophthalmology. 1997;81(5): 391-395.  https://doi.org/10.1136/bjo.81.5.391
  28. Yamada N, Morishige N, Yanai R, Morita Y, Kimura K, Chikama T, Nomizu M, Sonoda KH, Nishida T. Open clinical study of eye drops containing the fibronectin-derived peptide PHSRN for treatment of persistent corneal epithelial defects. Cornea. 2012;1408-1413. https://doi.org/10.1097/ICO.0b013e31824afd6c
  29. Wirostko B, Rafii M, Sullivan DA, Morelli J, Ding J. Novel therapy to treat corneal epithelial defects: a hypothesis with growth hormone. The ocular surface. 2015;13(3):204-212.  https://doi.org/10.1016/j.jtos.2014.12.005
  30. Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W. Mastropasqua L. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332-1343. https://doi.org/10.1016/j.ophtha.2018.02.022
  31. Recommendation for maintenance of orphan designation at the time of marketing authorization. August 25, 2017. https://www.ema.europa.eu/en/documents/orphan-review/recommendation-maintenance-orphan-designation-time-marketing-authorisation-oxervate-cenegermin_en.pdf
  32. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol. 1975;93:1039-1043.
  33. Tsubota K, Goto E, Shimmura S. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology.1999;106:1984-1989. https://doi.org/10.1016/S0161-6420 (99)90412-8
  34. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467-1474. https://doi.org/10.1007/s00347-002-0661-6
  35. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimized protocol for the production of autologous serum eye drops. Graefe’s Arch Clin Exp Ophthalmol. 2005;243(7):706-714.  https://doi.org/10.1007/s00417-004-1106-5
  36. Jeng BH, Dupps Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104-1108. https://doi.org/10.1097/ICO.0b013e3181a2a7f6
  37. Choi JA, Chung SH. Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects. Eye & contact lens. 2011;37(6):370-373.  https://doi.org/10.1097/ICL.0b013e318233c9bb
  38. Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye. 2009;23(2):290.  https://doi.org/10.1038/sj.eye.6703079
  39. Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Current eye research. 2013;38(1):9-17.  https://doi.org/10.3109/02713683.2012.720340
  40. Yoon KC. Use of umbilical cord serum in ophthalmology. Chonnam medical journal. 2014;50(3):82-85.  https://doi.org/10.4068/cmj.2014.50.3.82
  41. Erdem E, Yagmur M, Harbiyeli I, Taylan-Sekeroglu H, Ersoz R. Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects. International journal of ophthalmology. 2014;7(5):807.  https://doi.org/10.3980/j.issn.2222-3959.2014.05.12
  42. Vajpayee RB, Mukerji N, Tandon R, Sharma N, Pandey RM, Biswas NR, Melki SA. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. British Journal of Ophthalmology. 2003;87(11):1312-1316. https://doi.org/10.1136/bjo.87.11.1312
  43. Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. American journal of ophthalmology. 2007;144(1):86-92.  https://doi.org/10.1016/j.ajo.2007.03.016
  44. Kasparov AA, Kasparova EA, Pavlyuk AS. Local express autocytocinetherapy (a complex of cytokines) in the treatment of viral and virus-free eye lesions. Vestnik oftal’mologii. 2004;120(1):29-32. (In Russ.).
  45. Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-β1 — induced myodifferentiation. Investigative ophthalmology visual science. 2011;52(9):6066-6073. https://doi.org/10.1167/iovs.11-7302
  46. Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Japanese journal of ophthalmology. 2012;56(6):544-550.  https://doi.org/10.1007/s10384-012-0175-y
  47. López-Plandolit S, Morales MC, Freire V, Etxebarría J, Durán JA. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010;29(8):843-848.  https://doi.org/10.1097/ICO.0b013e3181a81820
  48. Abu-Ameerh MA, Jafar HD, Hasan MH, Al Bdour MD, Msallam M, Ababneh OH, Awidi AS. Platelet lysate promotes re-epithelialization of persistent epithelial defects a pilot study. International ophthalmology. 2018;1-8.  https://doi.org/10.1007/s10792-018-0968-1
  49. Huang CJ, Sun YC, Christopher K, Pai ASI, Lu CJ, Hu FR, Chen WL. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PloS one. 2017;12(2):1-16.  https://doi.org/10.1371/journal.pone.0171008
  50. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, de Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet. 1997;349(9057):990-993.  https://doi.org/10.1016/S0140-6736(96)11188-0
  51. Bezushko AV, Dubovikov AS, Kulikov AN, Churashov SV, Chernysh VF, Blinova MI, Gavrilyuk IO. Investigation of the possibility of using cultured autologous limbal epithelial stem cells on the collagen scaffold to treat the limbal deficiency in an experiment. Prakticheskaya medicina. 2017;9(2):67-71. (In Russ.).
  52. Sacchetti M, Rama P, Bruscolini A, Lambiase A. Limbal Stem Cell Transplantation: Clinical Results, Limits, and Perspectives. Stem cells international. 2018;12.  https://doi.org/10.1155/2018/8086269
  53. Eslani M, Baradaran-Rafii A, Ahmad S. Cultivated limbal and oral mucosal epithelial transplantation. In Seminars in Ophthalmology. 2012;27(3-4):80-93.  https://doi.org/10.3109/08820538.2012.680641
  54. Agorogiannis GI, Alexaki VI, Castana O, Kymionis GD.Topical application of autologous adipose-derived mesenchymal stem cells (MSCs) for persistent sterile corneal epithelial defect. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2012;250(3):455-457.  https://doi.org/10.1007/s00417-011-1841-3
  55. Holan V, Trosan P, Cejka C, Javorkova E, Zajicova A, Hermankova B, Cejkova J. A comparative study of the therapeutic potential of mesenchymal stem cells and limbal epithelial stem cells for ocular surface reconstruction. Stem cells translational medicine. 2015;4(9):1052-1063. https://doi.org/10.5966/sctm.2015-0039
  56. Calonge M, Pérez I, Galindo S, Nieto-Miguel T, López-Paniagua M, Fernández I, Herreras JM. A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. Translational Research. 2019;206:18-40.  https://doi.org/10.1016/j.trsl.2018.11.003

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.